VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	30.67	30.98	42.86	58.42	44.58
Short-Term Investments	62.63	0	0	1.03	28.78
Cash & Cash Equivalents	93.31	30.98	42.86	59.45	73.37
Cash Growth	201.23%	-27.72%	-27.91%	-18.97%	-46.15%
Receivables	0	0	7.58	15.82	0.14
Inventory	0	0	0	7.4	1.36
Other Current Assets	2.66	7.3	12.75	4.59	1.56
Total Current Assets	95.96	38.28	63.19	87.26	76.41
Property, Plant & Equipment	0.21	0	0.69	2.14	4.58
Other Long-Term Assets	1.52	2.48	3.17	4.35	0.17
Total Long-Term Assets	1.72	2.48	3.86	6.48	4.75
Total Assets	97.69	40.76	67.05	93.74	81.16
Accounts Payable	1.66	2.39	6.51	4.78	19.35
Current Debt	0.12	0	0.35	0.76	1.09
Other Current Liabilities	5.76	6.96	11.55	16.23	8.88
Total Current Liabilities	7.54	9.35	18.41	21.77	29.33
Long-Term Debt	0.1	0	0	34.03	33.38
Other Long-Term Liabilities	1.31	0	0	0.46	0.88
Total Long-Term Liabilities	1.41	0	0	34.48	34.26
Total Liabilities	8.95	9.35	18.41	56.25	63.58
Total Debt	0.21	0	0.35	34.78	34.47
Debt Growth	-	-	-99.00%	0.91%	-
Retained Earnings	-691.34	-662.74	-639.53	-566.2	-310.59
Comprehensive Income	0.03	0	0	0	0.01
Shareholders' Equity	88.74	31.2	48.64	37.49	17.58
Net Cash / Debt	93.09	30.98	42.51	24.66	38.9
Net Cash / Debt Growth	200.54%	-27.13%	72.36%	-36.60%	-71.45%
Net Cash Per Share	9.06	9.72	14.87	13.69	82.51
Working Capital	88.43	28.93	44.78	65.49	47.09
Book Value Per Share	8.64	9.79	17.01	20.82	37.28

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).